ATE277058T1 - Polyazomacrocyclofluoromonoalkylphosphensäure, ihre komplexe zur verwendung als kontrastmittel - Google Patents

Polyazomacrocyclofluoromonoalkylphosphensäure, ihre komplexe zur verwendung als kontrastmittel

Info

Publication number
ATE277058T1
ATE277058T1 AT97908699T AT97908699T ATE277058T1 AT E277058 T1 ATE277058 T1 AT E277058T1 AT 97908699 T AT97908699 T AT 97908699T AT 97908699 T AT97908699 T AT 97908699T AT E277058 T1 ATE277058 T1 AT E277058T1
Authority
AT
Austria
Prior art keywords
complexes
contrast agents
acid
polyazomacrocyclofluoromonoalkylphosphenic
polyazamacrocyclofluoromonoalkylphosphonic
Prior art date
Application number
AT97908699T
Other languages
English (en)
Inventor
Garry E Kiefer
A Dean Sherry
Original Assignee
Dow Global Technologies Inc
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dow Global Technologies Inc, Univ Texas filed Critical Dow Global Technologies Inc
Application granted granted Critical
Publication of ATE277058T1 publication Critical patent/ATE277058T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6515Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having three nitrogen atoms as the only ring hetero atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6524Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having four or more nitrogen atoms as the only ring hetero atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT97908699T 1996-02-23 1997-02-21 Polyazomacrocyclofluoromonoalkylphosphensäure, ihre komplexe zur verwendung als kontrastmittel ATE277058T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/606,162 US5834456A (en) 1996-02-23 1996-02-23 Polyazamacrocyclofluoromonoalkylphosphonic acids, and their complexes, for use as contrast agents
PCT/US1997/002799 WO1997031005A1 (en) 1996-02-23 1997-02-21 Polyazamacrocyclofluoromonoalkylphosphonic acids, and their complexes, for use as contrast agents

Publications (1)

Publication Number Publication Date
ATE277058T1 true ATE277058T1 (de) 2004-10-15

Family

ID=24426818

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97908699T ATE277058T1 (de) 1996-02-23 1997-02-21 Polyazomacrocyclofluoromonoalkylphosphensäure, ihre komplexe zur verwendung als kontrastmittel

Country Status (6)

Country Link
US (1) US5834456A (de)
EP (1) EP0882055B1 (de)
AT (1) ATE277058T1 (de)
AU (1) AU2054097A (de)
DE (1) DE69730820T2 (de)
WO (1) WO1997031005A1 (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6019959A (en) * 1997-07-31 2000-02-01 Schering Aktiengesellschaft Oligomeric compounds that contain perfluoroalkyl, process for their production, and their use in NMR diagnosis
US6565828B2 (en) * 2000-04-07 2003-05-20 Bristol-Myers Squibb Company Macrocyclic chelants for metallopharmaceuticals
US6776977B2 (en) 2001-01-09 2004-08-17 Bristol-Myers Squibb Pharma Company Polypodal chelants for metallopharmaceuticals
US7048907B2 (en) * 2001-02-05 2006-05-23 Biophysics Assay Laboratory, Inc. Synthesis, compositions and methods for the measurement of the concentration of stable-isotope labeled compounds in life forms and life form excretory products
US6670456B2 (en) * 2001-02-28 2003-12-30 Dow Global Technologies Inc. Actinium-225 complexes and conjugates for targeted radiotherapy
US6911017B2 (en) * 2001-09-19 2005-06-28 Advanced Cardiovascular Systems, Inc. MRI visible catheter balloon
US20040115822A1 (en) * 2002-09-12 2004-06-17 Schapaugh Randal Lee Methods of measuring the dissolution rate of an analyte in a non-aqueous liquid composition
US20060210479A1 (en) * 2004-08-10 2006-09-21 Dow Global Technologies Inc. Targeting chelants and chelates
TR201808537T4 (tr) 2004-09-23 2018-07-23 Genentech Inc Sistein değiştirilmiş antikorlar ve konjugatlar.
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
RS53168B (en) 2006-05-30 2014-06-30 Genentech Inc. Antibodies and Immunoconjugates and Their Use
PT2845866T (pt) 2006-10-27 2017-08-09 Genentech Inc Anticorpos e imunoconjugados e utilizações dos mesmos
KR20090114443A (ko) 2007-02-09 2009-11-03 제넨테크, 인크. 항-Robo4 항체 및 그의 용도
AU2008276128B2 (en) 2007-07-16 2013-10-10 Genentech, Inc. Humanized anti-CD79b antibodies and immunoconjugates and methods of use
ES2381788T3 (es) 2007-07-16 2012-05-31 Genentech, Inc. Anticuerpos anti-CD79b e inmunoconjugados y métodos de uso
IL287292B (en) 2008-01-31 2022-09-01 Genentech Inc and fusion antibody-drug-cd79b engineered antibodies cysteine-
US20110166444A1 (en) * 2008-09-22 2011-07-07 Koninklijke Philips Electronics N.V. Mri-visible sutures for minimally invasive image-guided anastomosis
CA2757382A1 (en) 2009-04-01 2010-10-21 Kristi Elkins Anti-fcrh5 antibodies and immunoconjugates
MX338775B (es) 2009-06-04 2016-05-02 Novartis Ag Metodos para identificacion de sitios para conjugacion de igg.
CA2781682A1 (en) 2009-12-04 2011-06-09 Genentech, Inc. Multispecific antibodies, antibody analogs, compositions, and methods
US8765977B2 (en) 2010-03-31 2014-07-01 General Electric Company Hydroxylated contrast enhancement agents and imaging method
US8722020B2 (en) 2010-03-31 2014-05-13 General Electric Company Hydroxylated contrast enhancement agents
US8362281B2 (en) 2010-03-31 2013-01-29 General Electric Company Intermediates for hydroxylated contrast enhancement agents
RU2613886C2 (ru) 2010-06-03 2017-03-21 Дженентек, Инк. Антитела и иммуноконъюгаты, визуализируемые при помощи иммуно-позитрон-эмиссионной томографии, и способы их применения
RU2755066C2 (ru) 2010-06-08 2021-09-13 Дженентек, Инк. Полученные с помощью генной инженерии антитела с цистеиновыми заменами и их конъюгаты
RU2630296C2 (ru) 2012-07-04 2017-09-06 Ф. Хоффманн-Ля Рош Аг Антитела к биотину и способы их применения
SI2869837T1 (sl) 2012-07-04 2016-12-30 F. Hoffmann-La Roche Ag Protitelesa proti teofilinu in postopki uporabe
NZ701040A (en) 2012-07-04 2017-02-24 Hoffmann La Roche Covalently linked antigen-antibody conjugates
EP3960768A1 (de) 2014-01-03 2022-03-02 F. Hoffmann-La Roche AG Bispezifische anti-hapten-/anti-blut-hirn-schranke-rezeptor-antikörper, komplexe davon und deren verwendung als blut-hirn-schranke-shuttles
CA2930046A1 (en) 2014-01-03 2015-07-09 F. Hoffmann-La Roche Ag Covalently linked polypeptide toxin-antibody conjugates
CA2930154A1 (en) 2014-01-03 2015-07-09 F. Hoffmann-La Roche Ag Covalently linked helicar-anti-helicar antibody conjugates and uses thereof
SG11201701128YA (en) 2014-09-12 2017-03-30 Genentech Inc Cysteine engineered antibodies and conjugates
BR112017010775A2 (pt) 2014-12-17 2018-02-27 Hoffmann La Roche ?método para produzir um produto de conjugação enzimática?
CN104945312A (zh) * 2015-06-24 2015-09-30 黄荣辉 一种2,6-二氯甲基吡啶盐酸盐的制备方法
EP3353310B1 (de) 2015-09-25 2020-04-29 H. Hoffnabb-La Roche Ag Verfahren zur herstellung von thioestern unter verwendung einer sortase a
WO2017050889A1 (en) 2015-09-25 2017-03-30 F. Hoffmann-La Roche Ag Recombinant immunoglobulin heavy chains comprising a sortase conjugation loop and conjugates thereof
CN108026560A (zh) 2015-09-25 2018-05-11 豪夫迈·罗氏有限公司 在低共熔溶剂中使用分选酶的转酰胺反应
CN108138158B (zh) 2015-09-25 2021-11-09 豪夫迈·罗氏有限公司 可溶性分选酶a
EP3436578B1 (de) 2016-03-30 2022-01-19 F. Hoffmann-La Roche AG Verbesserte sortase
CN110709523B (zh) 2017-04-12 2023-07-11 豪夫迈·罗氏有限公司 使用经pictet spengler反应获得的加标签的核苷的测序反应方法
CN111133008A (zh) 2017-07-13 2020-05-08 豪夫迈·罗氏有限公司 Pivka的新结合剂和测定
WO2019077113A1 (en) 2017-10-20 2019-04-25 F. Hoffmann-La Roche Ag COPY PROTECTION FOR ANTIBODIES
CN111918876B (zh) 2017-11-30 2024-02-02 豪夫迈·罗氏有限公司 抗pd-l1抗体及使用其检测pd-l1的方法
BR112020017941A2 (pt) 2018-03-14 2021-02-17 F. Hoffmann-La Roche Ag anticorpos, moléculas de ácido nucleico, vetor, composição e método de determinação da troponina t cardíaca humana
WO2019175131A1 (en) 2018-03-14 2019-09-19 F. Hoffmann-La Roche Ag Method for affinity maturation of antibodies
CN111936522A (zh) 2018-04-18 2020-11-13 豪夫迈·罗氏有限公司 新型抗胸苷激酶抗体
EP3844503B1 (de) 2018-08-31 2024-05-29 F. Hoffmann-La Roche AG Thymidinkinase (tk-1) in prognostischen indizes für dlbcl
CN116271117A (zh) 2018-09-28 2023-06-23 伊麦吉纳博公司 Cd8成像构建体及其使用方法
JP2023550278A (ja) 2020-10-30 2023-12-01 エフ. ホフマン-ラ ロシュ アーゲー 胆管癌のマーカーとしてのtimp1
WO2023111168A1 (en) 2021-12-17 2023-06-22 F. Hoffmann-La Roche Ag A novel antibody for detection of amyloid beta 42 (aβ42)

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5059412A (en) * 1984-06-04 1991-10-22 The Dow Chemical Company Macrocyclic aminophosphonic acid complexes for the treatment of calcific tumors
US5064633A (en) * 1984-06-04 1991-11-12 The Dow Chemical Company Macrocyclic aminophosphonic acid complexes, their formulations and use
US5362476A (en) * 1984-10-18 1994-11-08 Board Of Regents, The University Of Texas System Alkyl phosphonate polyazamacrocyclic cheates for MRI
US5342606A (en) * 1984-10-18 1994-08-30 Board Of Regents, The University Of Texas System Polyazamacrocyclic compounds for complexation of metal ions
US5188816A (en) * 1984-10-18 1993-02-23 Board Of Regents, The University Of Texas System Using polyazamacrocyclic compounds for intracellular measurement of metal ions using MRS
US5316757A (en) * 1984-10-18 1994-05-31 Board Of Regents, The University Of Texas System Synthesis of polyazamacrocycles with more than one type of side-chain chelating groups
US4639364A (en) * 1984-11-14 1987-01-27 Mallinckrodt, Inc. Methods and compositions for enhancing magnetic resonance imaging
US4778926A (en) * 1985-08-21 1988-10-18 Merrell Dow Pharmaceuticals Inc. Gem-dihalo and tetrahalo-1,12-diamino-4,9-diaza-dodecanes
US4695654A (en) * 1985-08-21 1987-09-22 Merrell Dow Pharmaceuticals Inc. Gem-dihalo-1,8-diamino-4-aza-octanes
US4719313A (en) * 1985-08-21 1988-01-12 Merrell Dow Pharmaceuticals Inc. Gem-dihalo and tetrahalo-1,12-diamino-4,9-diaza-dodecanes
US4914240A (en) * 1985-08-21 1990-04-03 Merrell Dow Pharmaceuticals Inc. Gem-dihalo-1, 8-diamino-4-aza-octanes
DE3713842A1 (de) * 1987-04-22 1988-11-17 Schering Ag Substituierte cyclische komplexbildner, komplexe und komplexsalze, verfahren zu deren herstellung und diese enthaltende pharmazeutische mittel
GB8719041D0 (en) * 1987-08-12 1987-09-16 Parker D Conjugate compounds
DE3728525A1 (de) * 1987-08-24 1989-03-16 Schering Ag Mehrkernige substituierte komplexbildner, komplexe und komplexsalze, verfahren zu deren herstellung und diese enthaltende pharmazeutische mittel
GB8723438D0 (en) * 1987-10-06 1987-11-11 Amersham Int Plc Cationic complexes of technetium-99m
US5582980A (en) * 1989-07-17 1996-12-10 Tropix, Inc. Chemiluminescent 1,2-dioxetanes
US5284647A (en) * 1988-03-18 1994-02-08 Schering Aktiengesellschaft Mesotetraphenylporphyrin complex compounds, process for their production and pharmaceutical agents containing them
GB8903023D0 (en) * 1989-02-10 1989-03-30 Parker David Chemical compounds
US5236695A (en) * 1989-11-27 1993-08-17 Concat, Ltd. MRI image enhancement of bone and related tissue using complexes of paramagnetic cations and polyphosphonate ligands
JP2593963B2 (ja) * 1989-11-27 1997-03-26 コンキャット リミティド 常磁性カチオン及びポリホスホネートリガンドの錯体を用いての骨及び関連組織のmri像増強
IT1246380B (it) * 1990-04-12 1994-11-18 Bracco Spa Sali insolubili di lantanidi per la visualizzazione in risonanza magnetica nucleare del tratto gastro-intestinale
IE911297A1 (en) * 1990-04-18 1991-10-23 Celltech Therapeutics Ltd Tetra-aza macrocycles, processes for their preparation, and¹their use in magnetic resonance imaging
JPH06340556A (ja) * 1990-06-18 1994-12-13 Dow Chem Co:The イメージング剤としての大環状アミノホスホン酸錯体の使用
US5248498A (en) * 1991-08-19 1993-09-28 Mallinckrodt Medical, Inc. Fullerene compositions for magnetic resonance spectroscopy and imaging
US5410043A (en) * 1991-12-06 1995-04-25 Schering Aktiengesellschaft Process for the production of mono-N-substituted tetraaza macrocycles
CA2103556C (en) * 1991-12-10 2002-04-16 Garry E. Keifer Bicyclopolyazamacrocyclophosphonic acids, their complexes and conjugates, for use as contrast agents, and processes for their preparation
EP0673655A1 (de) * 1992-03-19 1995-09-27 Daikin Industries, Limited Mri kontrastmittel und diagnostikverfahren
DE4218744C2 (de) * 1992-06-04 1997-11-06 Schering Ag Verfahren zur Herstellung von N-ß-Hxdroxyalkyl-tri-N-carboxylalkyl-1,4,7,10-tetraazacyclododecan- und N-ß-Hydroxyalkyl-tri-N-carboxyalkyl-1,4,8,11-tetraazacyclotetradecan-Derivaten und deren Metallkomplexe
GB9216843D0 (en) * 1992-08-07 1992-09-23 Cancer Res Inst Contrast agents for medical imaging
JPH06181890A (ja) * 1992-10-06 1994-07-05 Terumo Corp Mri造影剤
US5385893A (en) * 1993-05-06 1995-01-31 The Dow Chemical Company Tricyclopolyazamacrocyclophosphonic acids, complexes and derivatives thereof, for use as contrast agents
DE4317588C2 (de) * 1993-05-24 1998-04-16 Schering Ag Fluorhaltige makrocyclische Metallkomplexe, Verfahren zu ihrer Herstellung, sowie ihre Verwendung
WO1994027644A1 (en) * 1993-06-02 1994-12-08 Bracco S.P.A. Iodinated paramagnetic chelates, and their use as contrast agents
JPH0797340A (ja) * 1993-06-03 1995-04-11 Terumo Corp Mri造影剤組成物
EP0730616B1 (de) * 1993-11-26 2003-02-05 Dow Global Technologies Inc. Verfahren zur herstellung von polyazamacrocylen
IT1265440B1 (it) * 1993-12-24 1996-11-22 Bracco Spa Formulazioni diagnostiche paramagnetiche e metodo d'uso delle stesse

Also Published As

Publication number Publication date
AU2054097A (en) 1997-09-10
EP0882055A1 (de) 1998-12-09
EP0882055B1 (de) 2004-09-22
WO1997031005A1 (en) 1997-08-28
DE69730820D1 (de) 2004-10-28
US5834456A (en) 1998-11-10
DE69730820T2 (de) 2005-09-29

Similar Documents

Publication Publication Date Title
ATE277058T1 (de) Polyazomacrocyclofluoromonoalkylphosphensäure, ihre komplexe zur verwendung als kontrastmittel
ATE227297T1 (de) 2-pyridylmethylen-polyazamacrocyclophosphonsäur n,ihre komplexe und derivate zur verwendung als kontrastmittel
ATE316377T1 (de) Tricyclopolyazamacrocyclophosphonsäuren, ihre komplexe und derivate, für eine verwendung als kontrastmittel
IL124593A0 (en) Substituted aryl or heteroarylamides having retinoid-like biological activity
DE69106135T2 (de) Quasi-azeotrope Mischungen zur Verwendung als Kältemittel.
MX9700557A (es) Dihidrobenzofuranos.
ATE238307T1 (de) Substituierte porphyrinen
BG103310A (en) Benzonaphthyridins as bronchial therapeutical means
AU9744298A (en) Substituted tetrahydronaphthaline and analogous compounds
DE69927688D1 (de) Antivirales Mittel in Kombination mit Strahlentherapie zur Verwendung in der Behandlung von Krebs
DE69938192D1 (en) Imidazonaphthyridine
CU23088A3 (es) Compuestos de tetra-hidropiridina.
BR9713176A (pt) Benzotiofenos amorfos,métodos de preparação e métodos de uso
AU2455600A (en) Apoptosis-inducing factor
BG103087A (en) Method for the preparation of naphthiridons and intermediate compounds
EP1132458A3 (de) Zusammensetzungen zum Entfernen von Kalkstein

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties